References
- Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of
Oral and Maxillofacial Surgeons Position Paper on Medication-Related
Osteonecrosis of the Jaw—2014 Update. J Oral Maxillofac Surg 2014;
72:1938-1956.
- Hohnecker JA. DearDoctor. PrecautionsAddedto the LabelofAredia and
Zometa. East Hanover, NJ, Novartis Oncology, 2004. p 2
- United States Food and Drug Administration, Office of Drug Safety:
Postmarketing safety review. Bisphosphonates. Available at:
http://www.fda.gov/ohrms/dockets/ac/05/briefing/20054095B2_03_04-FDA-Tab3.pdf.
Accessed October 09, 2019
- Lipton A, Steger GG, Figueroa J, et al. Randomized activecontrolled
phase II study of denosumab efficacy and safety in patients with
breast cancer-related bone metastases. J Clin Oncol 2007;
25:4431-4437.
- Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with
zoledronic acid for the treatment of bone metastases in patients with
advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28:5132-5139.
- Malan J, Ettinger K, Naumann E, Beirne OR. The relationship of
denosumab pharmacology and osteonecrosis of the jaws. Oral Surg Oral
Med Oral Pathol Oral Radiol 2012;114:671-676.
- Owosho AA, Blanchard A, Levi L, et al. Osteonecrosis of the jaw in
patients treated with denosumab for metastatic tumors to the bone: a
series of thirteen patients. J Craniomaxillofac Surg 2016; 44:265-270.
- Fleissig Y, Regev E, Lehman H. Sunitinib related osteonecrosis of jaw:
a case report. Oral Surg Oral Med Oral Pathol Oral Radiol
2012;113:e1-e3.
- Estilo CL, Fornier M, Farooki A, et al. Osteonecrosis of the jaw
related to bevacizumab. J Clin Oncol 2008;26:4037-4038.
- Nicolatou-Galitis O, Migkou M, Psyrri A, et al. Gingival bleeding and
jaw bone necrosis in patients with metastatic renal cell carcinoma
receiving sunitinib: report of 2 cases with clinical implications.
Oral Surg Oral Med Oral Pathol Oral Radiol 2012;113:234-238.
- Kim DW, Jung YS, Park HS, Jung HD. Osteonecrosis of the jaw related to
everolimus: a case report. Br J Oral Maxillofac Surg
2013;51:e302-e304.
- Owosho AA, Scordo M, Yom SK, et al. Osteonecrosis of the jaw a new
complication related to Ipilimumab. Oral Oncol 2015;51: e100-e101.
- Ponzetti A, Pinta F, Spadi R, et al. Jaw osteonecrosis associated with
aflibercept, irinotecan and fluorouracil: attention to oral district.
Tumori 2016;102.
- Mawardi H, Enzinger P, McCleary N, et al. Osteonecrosis of the jaw
associated with ziv-aflibercept. J Gastrointest Oncol 2016; 7:E81-E87.
- Nicolatou-Galitis O, Galiti D, Moschogianni M, et al. Osteonecrosis of
the jaw in a patient with acute myeloid leukemia, who received
azacitidine. J Cancer Metasta Treat. 2016;2:220-223.
- Nicolatou-Galitis O, Razis E, Galiti D, Vardas E, Tzerbos F,
Labropoulos S. Osteonecrosis of the jaw in a patient with chronic
myelogenous leukemia receiving imatinib: a case report with clinical implications. Forum Clin Oncol 2013;4:29-33.
- Owosho AA, Liang STY, Sax AZ, et al. Medication-related osteonecrosis
of the jaw: An update on the memorial sloan kettering cancer center
experience and the role of premedication dental evaluation in
prevention. Oral Surg Oral Med Oral Pathol Oral Radiol
2018;125:440–445
- Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with
ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;
363: 711–23.
- Kolokythas A, Olech E, Miloro M. Alveolar Osteitis: A Comprehensive
Review of Concepts and Controversies. Int J Dent 2010;2010:249073.
- Taberner-Vallverdú M, Nazir M, Sánchez-Garcés MÁ, et al. Efficacy of
different methods used for dry socket management: A systematic review.
Med Oral Patol Oral Cir Bucal 2015;20(5):e633-9.
- Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab:
long-term follow-up of 177 patients with metastatic melanoma. Clinical
Cancer Res: Off J Am Assoc Cancer Res 2012;18:2039–47.
- Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone
loss and joint destruction in adjuvant arthritis through
osteoprotegerin ligand. Nature 1999;402:304–9.
- Burki TK. Ipilimumab prolongs survival in advanced melanoma. Lancet
Oncol 2016;17(11):e481
- Donia M, Fagone P, Nicoletti F, et al. BRAF inhibition improves tumor
recognition by the immune system: Potential implications for
combinatorial therapies against melanoma involving adoptive T-cell
transfer. Oncoimmunology 2012; 1(9):1476-1483.
- Boni A, Cogdill AP, Dang P, et al. Selective BRAFV600E inhibition
enhances T-cell recognition of melanoma without affecting lymphocyte
function. Cancer Res 2010;70(13):5213-9.